2018 American Transplant Congress
The BEST Trial: A Prospective Randomized Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression
Previous large multicenter belatacept (BELA)-based CNI- and steroid-free immunosuppressive trials have not enrolled to completion due to safety concerns. The BEST Trial (Belatacept-based Early Steroid…2018 American Transplant Congress
B Cell Reconstitution: 36-Month Analysis of Patients Post-Alemtuzumab Induction Followed by Belatacept-Based Immunosuppression
Alemtuzumab induction combined with belatacept and rapamycin (ABR) maintenance immunotherapy effectively prevents costimulation blockade resistant rejection (CoBRR). We longitudinally investigated kinetics of repopulating B cell…2018 American Transplant Congress
A Comparison of Alemtuzumab versus Antithymocyte Globulin Induction in High-Risk, Non-Sensitized Renal Transplant Recipients
University of Illinois Hospital and Health Sciences System, Chicago.
Background: Lymphocyte depleting induction is routinely utilized in high immunologic risk renal transplant (RTx). African Americans (AA) have a relatively higher risk of rejection regardless…2018 American Transplant Congress
Comparing Outcomes between Induction Immunosuppressive Therapies in Simultaneous Heart/Kidney Transplantation
Virginia Commonwealth University, Richmond.
Introduction: There is no published data on the risks and benefits of Induction immunosuppression in simultaneous heart/kidney transplant (SHKT) patients.Methods: We analyzed all SHKT performed…2018 American Transplant Congress
Emergence of a Costimulation-Susceptible T Cell Repertoire Post-Alemtuzumab Induction
Kidney transplant patients treated with belatacept-based regimens without depletional induction have higher rates of costimulation blockade resistant rejection (CoBRR). In contrast, belatacept effectively prevents rejection…2018 American Transplant Congress
The Influence of Rabbit Antithymocyte Globulin (rATG) Dose on the Incidence of CMV Infection in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis. A Propensity Score Matched Cohort Analysis
rATG has become the agent of choice for induction therapy in sensitized patients and those receiving expanded criteria donors (ECD) allografts. However, the optimal dose…2017 American Transplant Congress
Impact of T-Cell Depletion on CMV-Specific Memory T and B Cell Homeostatic Proliferation After Kidney Transplantation.
Human CMV infection is the most common opportunistic infection after kidney transplantation, with a negative impact on kidney allograft outcome. Transplant recipients are at higher…2017 American Transplant Congress
Alemtuzumab Induction Is Safe, and Permits the Avoidance of Steroids in the Majority of Renal Transplant Recipients.
IntroductionThe introduction of alemtuzumab into routine clinical use has been hindered by safety concerns surrounding its prolonged effect on the lymphoid compartment. Here we report…2017 American Transplant Congress
Benefits of Induction in Recipients of Acute Renal Failure Donor Kidneys.
University of Michigan, Ann Arbor
Kidneys from donors with acute renal failure (ARF) are often discarded due to concerns for DGF and graft failure. Induction immunosuppression can be used to…2017 American Transplant Congress
National Variation in US Kidney Transplant Induction Therapy.
Antibody induction (IND) therapy in kidney transplantation (KTx) reduces acute rejection risk but adds to transplant cost. Currently, only IL2 Receptor antibodies (IL2R-Ab) have FDA…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 31
- Next Page »